Loading...

뉴스 목록

The first c-Met inhibitor approved by the FDA to market

2020-05-18


The first c-Met inhibitor approved by the FDA to market

On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patients with locally advanced or metastatic MET exon 14 jumping (METEX 14) mutations in non-small cell lung cancer (NSCLC).). The FDA also approved FoundationOne CDx (F1CDx) as a companion diagnostic product for Tabrecta.


Lung cancer is the most common type of cancer in the world. There were 2.1 million newly diagnosed lung cancer patients in the world in 2018, including 1.8 million deaths. Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), NSCLC accounts for about 85% of lung cancer patients, MET exon 14 jump mutation occurs in 3% -4% of newly diagnosed advanced NSCLC cases.


당사는 귀하의 웹사이트 이용을 더 잘 이해하기 위해 쿠키를 사용하고자 하며, 이는 향후 웹사이트 방문 시 귀하의 경험을 개선하는 데 도움이 될 것입니다. 브라우저 설정에서 이 설정을 변경할 수 있습니다. 쿠키 사용에 대한 자세한 내용은 개인정보 보호정책을 참조하세요.